The title of this short editorial is deliberately provocative. The fact is that, perhaps surprisingly, there are no major, or even remotely definitive studies of the subject. The article in this issue of Lupus by Xu and Wiernik 1 provides a thoughtful review hinting at a positive rather than a negative association between the two diseases.
Yet in the experience of this physician with 30 years' lupus practice, and currently with 2500 lupus patients on the clinic register, the association between lupus and cancer seems rare -unusually rare. The number of malignancies in this large patient cohort (remembered vividly) is low. These are patients with aberrations in their immune response. Patients treated for months and years with immunosuppressive drugs. Patients treated with intravenous infusions and transplants. Patients exposed to hospital admissions. Patients in whom, for example, abnormal cervical smear tests are extremely frequent. And yet, it appears to me, malignancy is rare. This observation is not supported as yet by statistically acceptable data.
Epidemiology will have to tread through the usual minefields. Lupus patients are young. Cancer is less frequent in this age group. Yet, the literature has numerous case reports and series reporting malignancy with lupus. My own group is as guilty as most in publishing anecdotal reports of the association (two of our papers are cited by Xu and Wiernick). In retrospect, we probably felt that there was likely to be an increased lymphoma=cancer risk in lupus patients, and wished to highlight the fact.
Certainly, a cousin of lupus -Sjogren's syndrome, is linked with lymphoma. Patient and animal data from many sources over the past 30 years, led by the observations of Norman Talal and colleagues, predict that some patients with primary Sjogren's syndrome will develop lymphoma -an important clinical observation. But Sjogren's syndrome -particularly the 40 year old with enlarged parotids, lymphadenopathy and anti-Ro -is a far cry from lupus -both clinically, and maybe in terms of malignancy risk.
It is possible that some published series concentrate on 'atypical' lupus (the series of nine patients pub-lished in this issue of Lupus, for example, has an average age of 38, and only one of the nine is reported as unequivocally anti-DNA antibody positive). Certainly, in our own published report, the association was more with Sjogren's syndrome than with 'classical' lupus.
It is conceivable that there may be a 'conservation factor' preserving the 'lupus haplotype' down the generations and offering protection from certain infections and plagues and possibly from malignancy. As the 'lupus haplotype' slowly emerges, it may prove possible to make comparisons with known haplotypes of a number of malignancies.
To judge whether these musings are right or wrong requires precise clinical work. Perhaps collaboration between cancer registry databases and lupus databases may begin to satisfy the epidemiologists. Some outstanding reviews on the subject are now appearing, notably those of Shoenfeld 2 and Ramsey-Goldman and Clarke. 3 A number of lupus centres are now actively studying the question of malignancy and lupus, with significant (and conflicting) data beginning to emerge: 'Increased risk of malignancy, notably non-Hodgkin's lymphoma and perhaps cervical cancer, should be regarded as a complication of SLE' 4 'In this comprehensive inception cohort of SLE no increase in relative risk of malignancy overall was found'. 5 Appropriately, Ramsey-Goldman and Clarke in their editorial, 3 highlight the need to establish multicentre studies to pool patient data -collaborative efforts which are already being initiated by groups in Canada.
In the meantime, careful case reporting, as in the study of Xu and Wiernik, 1 providing clear clinical details, is pivotal.
